Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-09-17
2001-11-27
Shah, Mukund J. (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S430000, C514S443000, C546S114000, C549S032000, C549S071000, C549S072000, C549S073000
Reexamination Certificate
active
06323214
ABSTRACT:
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to certain thiophene derivatives and their use in the practice of medicine as allosteric modulators of adenosine receptors.
Adenosine (Ado) is an autocoid (or local hormone) that modulates numerous functions in the cardiovascular and other organ systems. The actions of Ado are mediated by at least four subtypes of cell surface receptors called A
1
, A
2a
, A
2b
, and A
3
. Because of the ubiquity of adenosine receptors (AdoRs) throughout the human body, their indiscriminate activation may cause undesirable side effects. Therefore, it is desirable that drugs which are administered systemically to target these receptors have some degree of organ selectivity.
The overall function of Ado appears to be the regulation of the balance between oxygen (or energy) supply and consumption (or work). Ado increases oxygen supply by causing vasodilation and decreases oxygen consumption or work by inhibiting cellular functions, e.g., slowing of heart rate. Consistent with this protective function, A
1
AdoR agonists, Ado uptake blockers and Ado deaminase inhibitors have been shown to reduce cellular damage and dysfunction during hypoxia and ischemia. This protective role of Ado and A
1
AdoR agonists has been shown in heart, brain, liver, and intestines. This and other potentially beneficial actions of Ado have led to increased interest in the development of Ado-related drugs targeted to ameliorate conditions such as myocardial ischemia and stroke.
However, the widespread expression of Ado receptors and the lack of sufficiently selective adenosinc agonists have been a major impediment to the successful development of direct-acting AdoR agonists to exploit the cytoprotective properties of Ado.
A number of compounds known to modulate the action of neurotransmitters, hormones and peptides bind at sites distinct from, but functionally linked to, the primary recognition site of the respective receptors. This form of interaction between two different ligands at the same receptor protein, which may result in modulation in the form of enhancement or inhibition of each other's binding and function, is referred to as allosterism. Positive (enhancement) or negative (inhibition) allosterism are important mechanisms of action of various biologically active agents. Numerous allosteric interactions have been exploited. Among the most well known of these are the allosteric interactions between the GABA receptor and benzodiazepines; the atrial natriuretic factor (ANF) receptor and amiloride; the dextromethorphan binding site and ropizine; and the muscarinic receptor and gallamine. Allosteric modulation of the actions of Ado on the A,AdoR by several 2-amino-3-benzoylthiophenes on cultured cells, cardiac and brain preparations have been reported. The specificity of these compounds for A
1
AdoRs have also been demonstrated.
It would be advantageous to provide allosteric modulators of Ado as an alternative to direct-acting Ado agonists and nuclcoside uptake blockers, preferably those which can selectively modulate the response to Ado in only those organs or localized areas of a given organ in which production of Ado is increased.
It is therefore an object of the present invention to provide allosteric modulators of Ado function.
It is a further object of the present invention to provide allosteric modulators of Ado function which provide a more selective therapeutic effect than direct-acting AdoR agonists.
It is still a further object of the present invention to provide methods of administering allosteric modulators of Ado function which limit the times and locations at which significant release of Ado occurs so that systemic side effects are minimized.
SUMMARY OF THE INVENTION
Compounds useful as potent, yet selective allosteric modulators of adenosine receptors, with activity as AdoR agonists, and, in some cases, AdoR antagonists, and methods of preparation and use thereof, are disclosed.
The compound have the following general formulas IA, IB, and IC:
wherein:
R
1
is hydrogen, alkyl, substituted alkyl, or haloacetyl;
R
2
, R
3
, and R
4
are independently hydrogen, halogen, alkyl, substituted alkyl, aryl, heteroaryl, heterocyclic, lower alkenyl, lower alkanoyl, amino, trifluoromethyl, amino alkyl, nitro, or cyano;
t is 0, 1, 2, or3;
Z is NH, N—C(X)—NH-aryl, NC(X)—NH-alk, N—C(X)—O-alk, N—C(X)—O-alkaryl, N—C(X)—O—aryl, N(alk)
2
(
+
) (and an associated pharmaceutically acceptable anion such as F
−
, Cl
−
, Br
−
or I
−
), N—(Gr)
m
(Am)
n
(Alk)
p
(Ar)
q
, or CH—(Gr)
m
(Am)
n
(Alk)
p
(Ar)
q
,
wherein
Gr is —SO
2
—, —C(O)O—, or —C(O)—,
Am is —CH(NH
2
)—, an amino acid residue, or an amino protected amino acid residue,
Alk is hydrogen, alkylene, substituted alkylene, alkenylene or substituted alkenylene,
Ar is aryl or substituted aryl, wherein the substituents include one or more alkyl or substituted alkyl groups or one or more nitro groups,
m is 0 or 1
n, p, and q are independently 0, 1, or 2,
provided that at least one of m, n, p, and q is other than 0;
X is O, S or N-alk
R
5
and R
6
are independently hydrogen, alkyl, substituted alkyl, or taken together form a lower alkenyl ring of 5 or 6 members,
provided that if R
2
, R
3
, and R
4
are hydrogen, then, both R
5
and R
6
may be neither hydrogen nor methyl;
further provided that if R
2
and R
3
are hydrogen while R
4
is trifluoromethyl or if R
2
and R
4
are hydrogen while R
3
is chloro, then both R
5
and R
6
may not be methyl;
R
7
is hydrogen, alkyl, N(alk)
2
, substituted alkyl or OH (and the resulting tautomelic form in which the OH is tautomerized to a carbonyl and the imine is tautomerized to an NH group);
Y is nitrogen, CH, C—CN or C—C(O)OR
8
; and
wherein R
8
is hydrogen, alkyl or substituted alkyl.
The compounds can be used in a method for allosterically modulating adenosine receptors in a mammal, including a human. The methods involve administering an effective amount of a compound of formula IA, IB, or IC sufficient to moderate adenosine receptors to the mammal. Positive allosterism results in several beneficial effects, including cardioprotection, neuroprotection, analgesia, and treatment of sleep disorders, irritable bowel syndrome, irritable bladder, urge incontinence, and glaucoma. Negative allosterism results in several beneficial effects, including the ability to treat Alzheimer's disease and congestive heart failure.
The compounds can be used in a pharmaceutical formulation that includes a compound of formula IA, IB, or IC and one or more excipients. Various chemical intermediates can be used to prepare the compounds of formula IA, IB, or IC.
REFERENCES:
patent: 3558606 (1971-01-01), Tinney
patent: 5026698 (1991-06-01), Fujikawa et al.
patent: 5532233 (1996-07-01), Weber
patent: 5585385 (1996-12-01), Natsugari et al.
patent: 5593988 (1997-01-01), Tahara
patent: 5747486 (1998-05-01), Sohda
patent: 2233457 (1973-02-01), None
patent: 2323149 (1973-11-01), None
patent: 3724031 (1988-01-01), None
patent: 407955 (1991-01-01), None
patent: 393101 (1974-05-01), None
patent: 5345785 (1993-12-01), None
patent: 50011397 (1995-04-01), None
patent: 7304755 (1995-11-01), None
patent: 8337583 (1996-12-01), None
patent: 93/07129 (1993-04-01), None
patent: 96/14319 (1996-05-01), None
CAS/Routh et al., “Techykinin Receptors in the Spinal Cord”,Progress in Brain Research, 104: 93-108, 1995.
CAS/Chesselet et al., “Ischemic Damage in the Striatum of Adult Gerbils: Relative Sparing of Somatostatinergic . . . ”,Experimental Neurology, 110(2) 209-218, 1990.
CAS/Cragg, et al., “Tachykinin Antagonists in carotid Body Responsews to Hypoxia and Substance P in the Rat”,Respiration Physiology, 95(3): 295-310, 1994.
CAS/Benedek, et al., “Potentiation of Thermoregulatory and Analgesic Effects of Morphine by Calcium Antagonists”,Pharm. Res. Comm., 16(10): 1009-1018, 1994.
CAS/Ghio, et al., “Clinical Evaluation of Calcium-Antagonist Dgs”,J. Card. Pharm., 20:S71-74 1992.
CAS/Zhou, et al., “Effects of Calcium Blockers on the Performance of Left
Medco Research, Inc
Roberts Abokhair & Mardula LLC
Shah Mukund J.
Truong Tamthom N.
LandOfFree
Allosteric adenosine receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Allosteric adenosine receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allosteric adenosine receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2608281